Skip to Content

Mesoblast Ltd ADR MESO

Morningstar Rating
$2.04 +0.07 (3.55%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MESO is trading at a 51% discount.
Price
$2.06
Fair Value
$8.39
Uncertainty
Extreme
1-Star Price
$82.18
5-Star Price
$9.27
Economic Moat
Kcvs
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MESO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.97
Day Range
$1.992.06
52-Week Range
$1.6110.24
Bid/Ask
$1.50 / $2.10
Market Cap
$175.06 Mil
Volume/Avg
53,674 / 235,726

Key Statistics

Price/Earnings (Normalized)
Price/Sales
21.20
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
83

Comparables

Valuation

Metric
MESO
ICVX
EWTX
Price/Earnings (Normalized)
Price/Book Value
0.353.303.69
Price/Sales
21.20
Price/Cash Flow
Price/Earnings
MESO
ICVX
EWTX

Financial Strength

Metric
MESO
ICVX
EWTX
Quick Ratio
1.8617.5918.98
Current Ratio
1.9518.0619.50
Interest Coverage
Quick Ratio
MESO
ICVX
EWTX

Profitability

Metric
MESO
ICVX
EWTX
Return on Assets (Normalized)
−29.30%−24.36%
Return on Equity (Normalized)
−31.87%−25.87%
Return on Invested Capital (Normalized)
−34.69%−29.82%
Return on Assets
MESO
ICVX
EWTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRSlnv$550.4 Bil
VRTX
Vertex Pharmaceuticals IncVmtjdyw$111.8 Bil
REGN
Regeneron Pharmaceuticals IncGcqtkyj$107.9 Bil
MRNA
Moderna IncHrcf$36.3 Bil
ARGX
argenx SE ADRKdqfj$23.0 Bil
BNTX
BioNTech SE ADRCqdlf$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncGddpcx$19.2 Bil
BMRN
Biomarin Pharmaceutical IncPnlhtyz$16.4 Bil
RPRX
Royalty Pharma PLC Class AMztxdg$13.4 Bil
INCY
Incyte CorpKmchr$13.3 Bil

Sponsor Center